Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease
Status: | Recruiting |
---|---|
Conditions: | Orthopedic |
Therapuetic Areas: | Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/16/2019 |
Start Date: | February 13, 2019 |
End Date: | June 30, 2022 |
Contact: | Pahoua Lee |
Email: | plee@rtix.com |
Phone: | 952-698-9930 |
Clinical Evaluation of Fortilink® TETRAfuse® Interbody Fusion Device in Subjects With Degenerative Disc Disease (FORTE)
This is a prospective, multi-center, non-randomized post-market evaluation designed to
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.
This is a prospective, multi-center, non-randomized post-market evaluation designed to
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.
There will be 3 arms in the study, one for each configuration of the Fortilink IBF system
(Fortilink-C, Fortilink-TS and Fortilink-L). Up to 50 subjects will be enrolled in each study
arm for a total of up to 150 subjects at up to 20 sites in the United States (US) and
European Union (EU).
collect and evaluate data on the safety and performance of the Fortilink IBF System with
TETRAfuse 3D Technology.
There will be 3 arms in the study, one for each configuration of the Fortilink IBF system
(Fortilink-C, Fortilink-TS and Fortilink-L). Up to 50 subjects will be enrolled in each study
arm for a total of up to 150 subjects at up to 20 sites in the United States (US) and
European Union (EU).
Inclusion Criteria:
- The subject is skeletally mature and at least 18 years of age.
- The subject has degenerative disc disease (DDD) of the cervical spine with
accompanying radicular symptom at one or two contiguous levels (Fortilink-C), or the
subject has DDD and ≤ Grade 1 spondylolisthesis of the lumbar spine at one or two
contiguous levels (Fortilink-TS and Fortilink-L).
- Subject plans to undergo one of the following procedures:
An anterior cervical interbody fusion at one to two continuous levels from C2-C3 to C7-T1
using autogenous or allogenic bone graft and supplemental fixation cleared and indicated
for use at the proposed treatment level(s) (Fortilink-C), or
An interbody fusion in the lumbar spine at one to two continuous levels from L1-L2 to L5-S1
using autogenous or allogenic bone graft and supplemental fixation cleared and indicated
for use at the proposed treatment level(s) (Fortilink-TS and Fortilink-L).
- The subject has undergone non-operative treatment of at least six weeks (Fortilink-C)
or at least six months (Fortilink-TS and Fortilink-L) prior to treatment with the IBF
system.
- The subject is willing and able to provide informed consent.
- The subject is willing and able to attend the protocol required follow-up visits and
examinations.
Exclusion Criteria:
- The subject has an active infection
- The subject has had prior fusion attempt(s) or is undergoing revision of a previously
implanted system at the involved level(s).
- The subject is a worker's compensation case, in active litigation related to the
procedure or is a prisoner or ward of the state.
- The subject meets one or more of the contraindications outlined in the IFU.
- The subject is pregnant, nursing, or is planning to become pregnant in the next year.
- The subject has documented evidence of current substance abuse.
- The subject has other concurrent medical condition that, in the opinion of the
investigator, does not make the subject a good candidate for the study.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials